EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune checkpoint inhibitor resistance in hepatocellular carcinoma

Zhijie Wang, Yichuan Wang, Peng Gao, Jin Ding

Cancer Letters · 2023-02 · 555 · 216038

DOI: 10.1016/j.canlet.2022.216038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-02. Verfasst von Zhijie Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 194-mal zitiert (Crossref) und nennt 125 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The application of immune checkpoint inhibitors (ICIs) has markedly enhanced the treatment of hepatocellular carcinoma (HCC), and HCC patients who respond to ICIs have shown prolonged survival. However, only a subset of HCC patients benefit from ICIs, and those who initially respond to ICIs may develop resistance. ICI resistance is likely related to various factors, including the immunosuppressive tumor microenvironment (TME), the absence of antigen expression and impaired antigen presentation, tumor heterogeneity, and gut microbiota. Therefore, exploring the possible mechanisms of ICI resistance is crucial to improve the clinical benefit of ICIs further. Various combination therapies for HCC immunotherapy have prevented and reversed ICI resistance to a certain extent. In addition, many new combination therapies that can overcome resistance are being explored. This review seeks to characterize the complex TME in HCC, explore the possible mechanisms of immune resistance to ICIs in different resistance categories, and review the combination therapies currently being applied and those under investigation for immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansImmune Checkpoint InhibitorsCombined Modality TherapyAntigen PresentationImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

Immune checkpoint blockadeImmune resistanceImmunotherapyLiver cancerTumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, 200433, China.
  • Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, 200433, China. Electronic address: gaopeng@smmu.edu.cn.
  • Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, Shanghai, 200433, China. Electronic address: dingjin@smmu.edu.cn.

Zitieren

APA

Wang, Z., Wang, Y., Gao, P., & Ding, J. (2023). Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Letters, 555, 216038. https://doi.org/10.1016/j.canlet.2022.216038

Vancouver

Wang Z, Wang Y, Gao P, Ding J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Letters. 2023;555:216038. doi:10.1016/j.canlet.2022.216038

BibTeX
@article{Wang2023,
  author = {Wang, Zhijie and Wang, Yichuan and Gao, Peng and Ding, Jin},
  title = {Immune checkpoint inhibitor resistance in hepatocellular carcinoma},
  journal = {Cancer Letters},
  year = {2023},
  volume = {555},
  pages = {216038},
  doi = {10.1016/j.canlet.2022.216038}
}
Kostenlos starten →